血脂康对老年人冠心病二级预防的作用  

Secondary prevention study of coronary heart disease in aged patients using Xuezhikang

作　　者：陆宗良[1] 杜保民[1] 武阳丰[1] 陈祚[1] 

机构地区：[1]中国医学科学院

出　　处：《中华老年医学杂志》2005年第11期805-808,共4页Chinese Journal of Geriatrics

基　　金：国家"九五"医学科技攻关项目(96-906-02-10)

摘　　要：目的探讨血脂康调整血脂对老年人冠心病的二级预防结果。方法对一项随机、双盲、安慰剂对照试验中的2550例老年和2320例非老年冠心病患者的干预结果进行对比分析。结果老年患者的各类临床事件的发生率远高于非老年患者。老年患者血脂康治疗组与对照组发生冠心病事件各为97例(7.6%)和164例(12.9%),治疗组减少41.3%(P<0.0001);死亡事件各发生92例(7.2%)和140例(11.0%),治疗组减少34.8%(P<0.001),其中冠心病死亡减少34.0%(P<0.01),肿瘤死亡减少57.6%(P<0.05)。未发现治疗组药物不良事件的增加。结论老年冠心病患者较非老年患者处于更高危状态,血脂康用于老年患者的冠心病二级预防是安全有效的。Objective To evaluate whether lipid-lowering therapy with Xuezhikang can reduce the risk of cardiac events and total mortality in aged coronary heart disease（CHD） patients. Methods 2550 aged and 2320 non-aged patients were selected and given with capsule Xuezhikang 0.6 g bid or placebo in addition to conventional therapy. The mean follow-up period was four years. Results The incidence of CHD events and the total mortality of aged patients were significantly higher than the non-aged. The incidence of CHD events was reduced by 41.3% for treatment group （P〈0.0001） in the aged patients. The total mortality were lowered by 34.8%（P〈0. 001） ,of which the death from CHD was reduced by 34.0% （P〈0.01）, the death from tumor was decreased by 57.6% （P〈0.05）. There was no significant difference in side effects and abnormal laboratory references between two groups. Conclusions Xuezhikang can reduce the risk of cardiac events and total mortality in aged CHD patients safely and effectively.

关 键 词：冠状动脉疾病 预防卫生服务 血脂康 

分 类 号：R541.4[医药卫生—心血管疾病] R589.205[医药卫生—内科学]